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‘Classical’ mutations in the EGFR tyrosine kinase domain (exons 18, 19 and 21) have been associated with sensitivity to tyrosine
kinase inhibitors (TKIs) in patients with NSCLC. The aim of the current study was to evaluate whether other than the classical
G719X, DEL19 and L858R mutations of EGFR confer sensitivity to TKIs. Genomic DNA was extracted from microdissected formalin-
fixed paraffin-embedded tumour tissue from 86 patients treated with gefitinib. Exons 18, 19 and 21 were amplified and subjected to
direct sequencing. Eleven (13%) patients harboured the classical exon’s 18, 19 and 21 mutations, while 14 (16%) had ‘other’ variants.
There was a significantly higher percentage of ‘never-smoker’ patients with ‘classical’ EGFR mutations (P¼0.002). Among patients
with ‘classical’ mutations 3 patients achieved PR and 7 SD, while in the ‘other’ mutations group 10 patients had SD as best response.
In the wild-type group, there were 3 patients with PR and 25 with SD. Median TTP was 16, 64 (P¼0.002) and 21 weeks and median
survival was 36, 78 and 67 weeks for patients with wild-type, ‘classical’ and ‘other’ EGFR mutations, respectively. The clinical relevance
of ‘other’ EGFR mutation variants remains uncertain and requires further assessment in a prospective study.
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Despite the use of newer chemotherapeutic agents, survival of
patients with advanced/metastatic NSCLC after first- or second-
line chemotherapy seems to have reached a plateau (Carney, 2002).
Further improvement in treatment is likely to require integration
of novel, molecular agents such as EGFR inhibitors. The BR.21
placebo-controlled trial of erlotinib demonstrated that therapy
with this EGFR tyrosine kinase inhibitor (TKI) was associated with
statistically significant and clinically relevant differences in terms
of overall and progression-free survival compared to the placebo
(Shepherd et al, 2005). Conversely, in a similar study with
gefitinib, (ISEL trial), a survival benefit was not demonstrated
(Thatcher et al, 2005). Several clinical factors have been correlated
with response to TKIs, including never-smoking status, female sex,
Asian ethnicity and adenocarcinoma histology (Fukuoka et al,
2003; Kris et al, 2003; Miller et al, 2004; Shepherd et al, 2005). In
addition, several groups have shown that somatic mutations in the
tyrosine kinase domain of the EGFR gene, in the exons 18 (G719A/
C/S), 19 (DEL19, in-frame deletions which eliminate four to six
amino acids just downstream of a critical lysine residue at position
745) and 21 (L858R) (commonly reported as ‘classical’ mutations),
were significantly correlated with clinical response to gefitinib
therapy (Lynch et al, 2004; Paez et al, 2004; Eberhard et al, 2005;
Tsao et al, 2005). Patients with ‘classical’ EGFR mutations exhibit
objective responses ranging from 75 to 95% (Huang et al, 2004;
Han et al, 2005; Mitsudomi et al, 2005; Taron et al, 2005; Tokumo
et al, 2005; Inoue et al, 2006; Yoshida et al, 2007). Furthermore,
recently it was reported that polysomy or amplification of the
EGFR gene but not EGFR mutational status was associated with
clinical outcome of patients treated with erlotinib (Hirsch et al,
2005; Tsao et al, 2005; Dziadziuszko et al, 2006).
Although classical EGFR mutations are present in most cases of
NSCLC responding to TKIs therapy, approximately 10–20% of
patients who do show a clinical response to gefitinib do not have
these EGFR mutations, indicating that other, than these classical
mutations, may confer sensitivity to TKIs, or that EGFR mutations
are not the sole determinants of TKI response (Sharma et al, 2007).
Since the original reports by Paez et al (2004) and Lynch et al
(2004) several ‘other’ mutations of EGFR gene have been reported
(Riely et al, 2006b). During sequence analysis performed by our
group, several mutations of EGFR’s exons 18, 19 and 21, other than
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sthe classical ones, which will be collectively reported in the text as
‘other’, have been identified; however, their biological as well as
their clinical relevance is still unclear (Marchetti et al, 2005). The
aim of the present study was to determine whether the presence of
these ‘other’ variants is correlated with the clinical outcome of
patients treated with gefitinib.
In the present study, the clinical outcome of NSCLC patients
treated with gefitinib in the context of an expanded access program
(EAP) was analysed according to the presence of classical or ‘other’
variants of EGFR mutations.
PATIENTS AND METHODS
Patient selection
Patients with histologically documented NSCLCs were included in
this retrospective analysis. Additional inclusion criteria were as
follows: a gefitinib treatment of at least 4 weeks (to evaluate
efficacy after adequate exposure to the drug); complete informa-
tion regarding tumour size, tumour location, extent of disease and
prior treatments for NSCLC; bi-dimensionally measurable disease
with imaging assessment performed at least 3 weeks before starting
gefitinib therapy and at least one subsequent imaging assessment;
tumour tissue was required for the assessment of EGFR mutations.
Expanded access program
Gefitinib EAP, was a non-randomised, open-label compassionate
use program, which enrolled patients with advanced/metastatic
NSCLC. The EAP protocol and informed consent forms were
approved by the Scientific and Ethics Committees of the
participating Institutions. Patient enrollment began on July 2001
and was closed on April 2006. Eligible patients with NSCLCs
(agedX18 years) were those who either (i) had disease progression
with standard systemic chemotherapy or radiation therapy, or (ii)
were ineligible for chemotherapy or radiation therapy, finally.
Treatment
Gefitinib was administered orally, as a once daily dose of 250mg.
Treatment was continued until disease progression, the appear-
ance of unacceptable toxicity or patient’s withdrawal of consent.
Objective tumour responses were evaluated according to WHO
response criteria (Miller et al, 1981).
Immunohistochemistry
Representative, tumour sections from formalin-fixed paraffin-
embedded (FFPE) tumour samples were stained immuno-
histochemically, as described previously (Koutsopoulos et al,
2007), using the mouse monoclonal anti-EGFR antibody (clone
H11, code M3563, DakoCytomation, Glostrup, Denmark), in
dilution 1/50 and incubation time 1h at room temperature. For
the detection of antigen–antibody reaction the Ultra-Vision
detection system AP Polymer kit (catalogue no. TL-125-AL, Lab
Vision, Cheshire, UK), was used according to the manufacturer’s
instructions. Immunoreaction was considered as weakly positive
(2þ) when more than 10% of the tumour cells showed weak to
moderate complete membrane staining or as strongly positive
(3þ) when a strong complete membrane staining was observed in
more than 10% of the tumour cells. All other staining patterns
were interpreted as negative (0 or 1þ) (Koutsopoulos et al, 2007).
DNA extraction and mutation analysis
All tumour samples were FFPE tissues. Representative sections
from tissue used for DNA extraction were stained with H&E and
subjected to histopathologic examination. Subsequently, tissue
samples were macrodissected or microdissected (piezo power
Eppendorf Microdissector, Germany) to ensure that specimens
contained at least 80% tumour cells. Approximately 5–10mm
sections or 30–100000 cells were collected from normal (when
available) and tumour samples and placed in 2% SDS/proteinase K
(10mgml
 1)a t5 6 1C overnight. DNA was extracted from the FFPE
tissue using the MasterPure Complete DNA/RNA Purification kit
(EPICENTRE; Biotechnologies, Madison, USA) according to the
manufacturer’s instructions. Exons 18, 19 and 21 were amplified and
subjected to direct sequencing. The PCR primers were as follows:
155273L23(18ex) 50-TCCCAAACACTCAGTGAAACAAA-30, 155348
L22(18ex) 50-TGGTCTCACAGGACCACTGATT-30, 154838U22(18)
50-TCAGAGCCTGTGTTTCTACCAA-30, 154899U20(18) 50-TCCAA
ATGAGCTGGCAAGTG-30, 55634U24(19ex) 50-AAATAATCAGTGT
GATTCGTGGAG-30, 156027L20(19) 50-TGTGGAGATGAGCAGGG
TCT-30, 156107L22(19ex) 50-GAGGCCAGTGCTGTCTCTAAGG-30,
155750U20(19) 50-GTGCATCGCTGGTAACATCC-30, 173160L22
(21Ex) 50-CAGCTCTGGCTCACACTACCAG-30, 173076L19(21) 50-
CATCCTCCCCTGCATGTGT-30, 172656U22(21Ex) 50-GCAGCGGG
TTACATCTTCTTTC-30, 172747U19(21) 50-GCTCAGAGCCTGGCA
TGAA-30. The first PCR was carried out in total volume of 10ml
containing 1/10 of the extracted genomic DNA using 1U of
Platinum Taq DNA polymerase (Invitrogen Corporation, Carlsbad,
CA, USA). The initial denaturing step was 941C for 15min,
followed by 35 cycles of denaturing step at 941C for 20s, annealing
step at 601C for 30s and extension step at 721C for 1min, ending
with a final extension step at 721C for 7min. Nested PCR was
carried in a total volume of 20ml and the conditions were identical
to the first PCR. Cycle sequencing reactions were performed using
the nested PCR primers and the ABI BigDye Terminator kit (v3.1,
Applied Biosystems, Foster City, CA, USA) and electrophoresed on
an ABI3100 genetic analyzer (Applied Biosystems). Sequence
variants were determined using the Seqscape software (Applied
Biosystems) and confirmed by an independent PCR amplification
and sequencing in both directions.
Statistical analysis
Descriptive statistics for the patient group are reported as median
and range. Statistical comparisons between group rates (propor-
tions) were assessed by Pearson’s w
2-test or Fisher’s test where
appropriate (Altman, 1991). As this was a compassionate use
program, the primary outcome variables were safety, survival and
assessment of response. Overall survival (OS) was measured from
entry into the study until death; 1-year survival was estimated
using the Kaplan–Meier method (Collet, 1994).
RESULTS
Patients’ demographics
Eighty-six patients with a median age of 61 years (range¼35–82)
were enrolled in the present analysis. Most of the patients (75%)
were male, 53 (61.6%) had an adenocarcinoma histology and 61
(79%) had stage IV disease. A total of 28 (33%) patients were
never-smokers. All patients had received a platinum-based
chemotherapy, except two patients with severe heart failure, which
precluded cisplatin administration. A total of 66 patients had
gefitinib as third-line treatment; 14 patients (21%) received taxane-
based second-line therapy, 21 (32%) a platinum-based therapy
while the remaining 31 (47%) received a gemcitabine or
irinotecan-based regimen as second-line treatment. Patients’
characteristics are presented in Table 1. EGFR membrane
expression was assessed by immunohistochemistry in all tumour
specimens; A total of 42 (49%) of these specimens were considered
as positive (2þ or 3þ) for EGFR expression.
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sMutational analysis
EGFR mutation detection was performed by sequencing exons 18,
19 and 21 in tumours of all patients (n¼86) and matched-normal
tissue (n¼22) or blood (n¼3) of patients carrying EGFR
mutations.
According to the mutational status, three groups of patients
were identified as follows: (i) the ‘wild-type’ group (n¼61
patients; 71%) with no detectable mutations; (ii) ‘classical’
mutations group (n¼11 patients, 13%; 6 of these patients
harboured the classical exon 19 deletion, one the G719D, one the
E746V and three the exon 21 L858R point mutation) and (iii) the
‘other’ mutations group (n¼14 patients, 16%). EGFR mutational
status is presented in Table 2. None of the reported EGFR
mutations was found in matched-normal tissues suggesting their
somatic origin and eliminating the possibility to be single-
nucleotide polymorphisms. A total of 8 (57%) cases had ‘other’
mutations that have been previously reported and 6 cases had
novel EGFR mutations.
A total of 1 (1.1%) patient (no. 13) had two ‘other’ mutations,
while 3 (3.4%) patients (nos. 9, 11 and 18), who were included in
the ‘classical mutations’ group, had both the exon 21 L858R
mutation and an ‘other’ mutation (Table 3). The incidence of
‘classical’ mutations was gender – (9.4% for males vs 22.7% for
females; P¼0.139) and histology – (11.8% in adenocarcinomas vs
14.3% in non-adenocarcinomas; P¼0.752) independent, while it
was significantly higher in ‘never-smoker’ patients compared to
‘smokers’ (32 vs 2.1%, respectively; P¼0.001). Similarly, regarding
the ‘other’ variants, there was no difference in their incidence
according to sex (male vs female: 18.8 vs 13.6%, P¼0.750),
histology (adenocarcinoma vs other: 15.7 vs 20.0%, P¼0.773) and
smoking habits (smoker vs never-smoker: 20.8 vs 8.0%, P¼0.200).
Finally, no correlation was observed between EGFR expression as
assessed by IHC and presence of ‘classical’ mutations (P¼0.732);
conversely, the detection of ‘other’ variants was more frequent in
patients with tumours, which did not express EGFR by IHC (28.9
vs 8.3%, P¼0.036).
Treatment
The median duration of gefitinib administration was 17 weeks
(range¼4–140). The reason for treatment discontinuation was
disease progression in all but six (6.9%) patients (drug-related
toxicity (n¼3 patients) and personal reasons non-related to
treatment or the disease (n¼3 patients)). There was no clear
association between treatment duration and any of the following:
PS (P¼0.262), histology (P¼0.751), disease stage (P¼0.103),
smoking status (P¼0.950), sex (P¼0.663) and skin rash
(P¼0.357) and EGFR expression by IHC (P¼0.254). However,
patients belonging to the group with ‘classical’ mutations had
significantly longer treatment duration when compared with
patients of the ‘wild-type’ group (67 weeks vs 17 weeks,
respectively; P¼0.018), while there was a trend towards longer
treatment duration when compared with patients belonging to
group of ‘other’ mutations (67 vs 21 weeks, respectively; P¼0.069).
On the contrary, there was no significantly different treatment
duration between patients belonging to the ‘other’ mutations and
those of the ‘wild-type’ group (21 and 17 weeks, respectively;
P¼0.141).
Response to treatment
No patient achieved a complete response, while six (7.0%)
experienced a partial response (PR) (overall response rate¼7.0%;
95% CI¼1.59–12.36) and 40 (46.5%) stable disease (SD); the
disease control rate (DCR; PRþSD) was 53.5% (95% CI¼42.95–
64.03%). Additionally, progressive disease (PD) was observed in 40
(46.5%) patients. Disease control rate was significantly higher for
the following: (i) patients with PS 0–1 as compared with those with
PSX2 (67 and 22%, respectively; Po0.001); (ii) women as
compared to men (77.3 and 42.9%, respectively; P¼0.007); (iii)
never-smokers vs smokers (84 and 34%, respectively; Po0.001)
and (iv) patients who developed skin rash as compared with those
who did not (85.2 and 35.7%, respectively; P¼0.003). In addition,
there was a trend towards a higher DCR in patients with
adenocarcinoma compared with those bearing other histologic
types (54.9 and 47.1%, respectively; P¼0.057). Regarding patients
achieving SD, significant association was observed for those with a
PS of 0–1 (P¼0.003), never-smoker status (P¼0.001) and
development of skin rash (P¼0.003); conversely, there was no
association between DCR and sex (P¼0.053) or histology
(P¼0.355) (Table 4).
The DCR was significantly higher in patients of the ‘classical’
mutations than in patients of the ‘wild-type’ (90.9 and 43.3%,
respectively; P¼0.006) group; conversely, there was no significant
difference between the DCR observed in patients of the ‘classical’
mutations group and that of patients of the ‘other mutations’
group (90.9 and 57.1%, respectively; P¼0.090) or of patients of
the ‘other mutations’ group and those of the ‘wild-type’ group
(57.1 and 43.3%, respectively; P¼0.386). All patients (six out
of six) with exon 19 deletion achieved disease control (two patients
Table 1 Patients’ characteristics
n %
Age
Median 61
(minimum–maximum) 35–82
Sex
Male 64 75
Female 22 26
Histology
Adenocarcinoma 47 (53) 55 (61.6)
Squamous cell carcinoma 27 (29) 31 (33.7)
Large cell carcinoma 1 1 (1.1)
Bronchoalveolar 4 5 (4.7)
Other 7 8 (9.3)
PS (WHO)
0–1 53 62
X23 3 3 8
Stage
IIIB 25 21
IV 61 79
EGFR expression (IHC)
0–1+ 44 51
2–3+ 42 49
Line of therapy
2nd 20 24
X3rd 66 76
Smoking status
Smoker 39 45
Ex-smoker 19 22
Never-smoker 28 33
No. of organs involved
11 9 2 2
24 8 5 6
X31 9 2 2
Median (range) 2 (1–4)
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sachieved PR and four SD); in addition, two out of three patients
with exon 21 L858R mutation experienced disease control (one
patient with PR and one with SD) while both patients with the
G719D and E746V point mutations achieved SD. In the multi-
variate analysis, the presence of mutations (either ‘classical’, or
‘other’, as well as all patients with mutations) did not emerge as a
significant factor associated with DCR or SD.
Time to tumour progression
The median follow-up period was 109 weeks and the median time
to tumour progression (TTP) 20 weeks (range¼4–140). A total of
23 (36%) patients had a TTP424 weeks and 7 (10.9%) 452 weeks
(Table 5). There was no difference in TTP according to sex
(P¼0.468), histology (P¼0.676), EGFR positivity (by IHC)
Table 2 Results of EGFR mutational analysis
Patients
no.
‘Classical
mutations’
group
‘Other
mutations’
group Histology Gender Smoking status Response
1 DEL 19 Squamous Male Never-smoker SD
2 Y727H Squamous Male Smoker SD Y727C (273T cell line) reported
(Stabile et al, 2005)
3 DEL 19 Adenocarcinoma Male Never-smoker SD
4 V843I Squamous Male Ex-smoker SD V843I reported (Koyama et al,
2006)
5 L747S Adenocarcinoma Female Never-smoker SD L747P reported (Sunaga et al,
2007)
6 G719D Adenocarcinoma Male Never-smoker SD
7 DEL 19 Adenocarcinoma Female Never-smoker PR
8 P691S Adenocarcinoma Male Ex-smoker SD Novel
9 L858R, L861P Undifferentiated Male Smoker PD
10 K860E Squamous Male Smoker PD Novel
11 L858R, V843I Adenocarcinoma Female Never-smoker SD
12 G863S Adenocarcinoma Female Never-smoker SD G863D reported (Bell et al, 2005;
Chou et al, 2005; Riely et al, 2006b)
13 T847A, G863S Adenocarcinoma Male Smoker PD T847I reported (Tsao et al, 2005)
14 L692P Squamous Male Smoker PD Possible non-somatic
15 L703F Adenocarcinoma Female Smoker PD L703V reported (Takano et al,
2005; Riely et al, 2006b)
16 E746V Adenocarcinoma Female Never-smoker SD
17 G729R Undifferentiated Male Smoker PD G729E reported (Willmore-Payne
et al, 2006)
18 L858R, E709K Squamous Female Never-smoker PR
19 V726M Adenocarcinoma Male Smoker SD Novel
20 DEL19 Adenocarcinoma Male Never-smoker PR
21 DEL19 Squamous Male Never-smoker SD
22 G857E Adenocarcinoma Male Smoker SD Reported (Hsieh et al, 2006)
23 E711K Squamous Male Smoker PD Novel
24 DEL19 BAC Female Never-smoker SD
25 G874S Adenocarcinoma Female Smoker SD
Total 11 14
Table 3 Clinical characteristics of patients bearing both a classical and an ‘other’ mutation
Patients no. Sex Histology Smoking status Response to gefitinib Duration
9 Male Undifferentiated Smoker PD — L858R-L861P
11 Female Adenocarcinoma Never-smoker SD 64 weeks L858R-V843I
18 Female Squamous Never-smoker PR 12 weeks L858R-E709K
Table 4 Clinical and molecular characteristics of patients achieving disease control
n Female sex n (%)
Adenocarcinoma
histology
a n (%)
Never smoker
n (%)
Skin rash development
n (%) EGFR mutations
PR 6 4 (67%) 2 (33%) 5 (83) 4 (67%) DEL 19: n¼2 (33%)
L858R: n¼1 (17%)
Wild type: n¼3 (50%)
SD 40 14 (35%) 28 (70%) 18 (45%) 19 (47.5%)
DEL 19: n¼4 (10%)
L858R: n¼1 (2.5%)
Other variant: n¼10 (25%)
Wild type: n¼25 (62.5%)
PR¼partial response, SD¼stable disease.
aBronchoalveolar included.
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s(P¼0.267) and PS (P¼0.437); conversely, patients who had never-
smoked and patients who developed skin rash had significantly
higher TTP (P¼0.003 and P¼0.006, respectively). Time to
tumour progression in the ‘classical’ mutations group was
significantly longer than in the ‘wild-type’ group (64 vs 16 weeks;
P¼0.002, Figure 1). On the contrary, there was no difference in
TTP between ‘other’ mutations group and ‘wild-type’ group (21 vs
16 weeks; P¼0.363) while there was a trend towards a significant
difference in TTP between ‘other’ mutation group and ‘classical’
mutations group (21 vs 64 weeks; P¼0.069). Although patients
with DEL19 mutation had numerically higher TTP, when
compared with L858R mutation patients, this difference failed to
reach statistical significance (80 vs 64 weeks, P¼0.786).
Survival
Median OS was 48 weeks (range¼4–140). None of the following
factors had a significant impact on OS: PS (P¼0.403), histology
(P¼0.198), smoking (P¼0.242), sex (P¼0.475), skin rash
(P¼0.182) and EFGR IHC expression (P¼0.637). Median OS
was significantly longer in patients with the DEL19 mutation (not
reached) compared to ‘wild-type’ patients (36 weeks; P¼0.043,
Figure 2); however, when all patients with ‘classical’ mutations
were included in the analysis, this difference was lost (78 vs 36
weeks; P¼0.052, Figure 3); there was no statistically significant
difference regarding OS between patients with DEL19 and L858R
mutation (not reached vs 78 weeks, P¼0.896). Similarly, patients
of the ‘other’ mutation group had a median survival of 67 weeks,
which was not different when compared with ‘wild-type’ group
(P¼0.094) or ‘classical’ mutations group (P¼0.491). Efficacy
results according to mutational status are presented in Table 6.
DISCUSSION
The incidence of the classical somatic mutations has been reported
to range between 3 and 13% in Caucasian populations and between
30 and 40% in populations of Asian descent (Shigematsu et al,
2005; Calvo and Baselga, 2006). In a Greek study (Murray et al,
2006), somatic mutations of EGFR were reported in 15% of a group
of 60 patients with NSCLC, while Dova et al (2007) reported two
mutations in 50 Greek patients with cancer of unknown primary.
In our series, mutational analysis revealed the presence of
‘classical’ mutations in 11 (13%) patients which is in agreement
with other reports (Murray et al, 2006; Dova et al, 2007), while 14
(16%) patients had ‘other’ mutations. A similar high incidence of
‘other’ EGFR mutations has been reported by Tsao et al (2005) who
have also used microdissected FFPE tumour samples. Microdissec-
tion of tumour samples with a low percentage and/or uneven
distribution of cancer cells allows the detection of mutations with
higher sensitivity; this could be the reason for the high incidence of
Table 5 EGFR mutation status for patients with X24 and X52 weeks
TTP
TTP n Wild type
Exon 19
deletion L858R
Other
variant
X24 weeks 23 11 (48%) 5 (22%) 1 (4%) 6 (26%)
X52 weeks 7 1 (14%) 2 (29%) 1 (14%) 3 (43%)
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Figure 1 Kaplan–Meier curve of time to tumour progression (TTP)
of wild-type EGFR patients group, ‘classical’ and ‘other’ mutations group.
*P-value between ‘classical’ and wild type.
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Figure 2 Kaplan–Meier survival curve of wild-type EGFR patients group,
‘classical’ and ‘other’ mutations group.
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Figure 3 Kaplan–Meier survival curve of patients with the ‘classical’
DEL19 mutation and wild-type EGFR.
Table 6 Efficacy results according to mutational status
‘Classical’ mutations ‘Other’ mutations Wild type
DCR 90.9%* 57.1% 43.3
TTP 64 weeks* 21 weeks 16 weeks
OS 78 weeks** 67 weeks 36 weeks
DCR¼disease control rate, OS¼overall survival; TTP¼time to tumour progres-
sion. *Po0.05 (vs wild type). **P¼0.052 (vs wild type).
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low-DNA template input in PCR could generate false mutations.
However, in our case the latter is unlikely, given that the sequence
analysis of FFPE normal tissue specimens of 22 patients with EGFR
mutations revealed no mutations (data not shown).
The presence of ‘other’ mutations in our study was not
correlated with sensitivity to gefitinib. Indeed, patients whose
tumours harbour ‘other’ variants of EGFR mutations had a higher,
but not statistically significant, DCR when compared with patients
bearing wild-type EGFR. However, this observation should be
considered with caution given the small number of patients
analysed. On the other hand, tumour growth control was
significantly higher (P¼0.013) in patients who presented the
classical EGFR mutations compared to that of patients with wild-
type EGFR, as already has been reported (Argiris et al, 2003; Miller
et al, 2004; Han et al, 2005; Kim et al, 2005; Thatcher et al, 2005;
Tsao et al, 2005). Similarly, although patients with ‘other’ EGFR
mutations had a numerically longer survival as compared with
patients of the ‘wild-type’ group, this difference failed to reach
statistical significance. This observation may suggest that,
collectively, ‘other’ EGFR mutation variants per se could not be
considered as predictors of clinical outcome.
Furthermore, there was a trend towards higher survival for
patients with classical mutations, when compared with ‘wild-type’
patients, but this difference failed to reach statistical significance.
A possible reason for this observation is the small number of
patients studied. This observation is similar with that reported in
the BR.21 study (Tsao et al, 2005) but it is in conflict with that
reported by other studies (Hirsch et al, 2005; Takano et al, 2005).
However, patients with exon 19 deletions had significantly longer
survival than patients of the ‘wild-type’ group; it should be
interesting to mention that patients with EGFR exon 19 deletions
are reported to have a longer survival than patients with EGFR
L858R point mutations when treated with TKIs (Mitsudomi et al,
2005; Jackman et al, 2006; Riely et al, 2006a).
In the original reports by Lynch et al (2004) and Paez et al
(2004), only one mutation per tumour was detected. However,
subsequent studies demonstrated the presence of more than one
mutation per tumour sample (Huang et al, 2004; Pao et al, 2004;
Taron et al, 2005; Murray et al, 2006). In the present study, four
patients had both a ‘classical’ and ‘other’ mutation variants; three
of them achieved SD (Table 3). However, definitive conclusions
cannot be drawn, given the small number of patients and the little
amount of data presented in the literature.
In summary, our findings demonstrate that classical but not
‘other’ mutation variants of EGFR gene are associated with a
higher DCR and better TTP; however, EGFR mutational status
should not be considered as the only predictor of response to TKIs
since disease control with gefitinib has also been observed in
patients without EGFR mutations. Patients harbouring ‘other’
EGFR mutation variants have a clinical comportment comparable
with that of patients with wild-type EGFR; although this
observation strongly suggests that these mutations per se could
not confer sensitivity to TKTs, we cannot exclude that some of
these mutations could be of clinical relevance. Therefore, it should
be of importance to establish a large international database of
‘other’ EGFR mutation variants, to better understand and evaluate
their clinical relevance.
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